TSH, Free T3 and Free T4: Understanding the Thyroid Panel

The hypothalamic-pituitary-thyroid axis

Thyroid function is regulated by a feedback loop: the hypothalamus releases thyrotropin-releasing hormone (TRH), which signals the pituitary to release thyroid-stimulating hormone (TSH), which in turn signals the thyroid gland to produce thyroxine (T4) and, in smaller amounts, triiodothyronine (T3). Circulating thyroid hormone feeds back to suppress TRH and TSH release — so, in a properly functioning axis, TSH and thyroid hormone move in opposite directions: as thyroid hormone falls, TSH rises to compensate, and vice versa.

TSH: what it measures and what it doesn't

TSH is the most commonly used first-line thyroid screening test because it is a sensitive indicator of how the pituitary "sees" thyroid hormone status, functioning as an early-warning marker: a high TSH indicates the thyroid is not making enough hormone (primary hypothyroidism), and in most healthy individuals a normal TSH indicates the thyroid is functioning properly.^[2] A normal TSH in a person with an intact hypothalamic-pituitary axis generally suggests adequate thyroid hormone signaling at the pituitary level. However, TSH is a pituitary signal, not a direct measurement of tissue-level thyroid hormone action — and it can be affected by pituitary or hypothalamic disorders, certain medications, acute illness, and normal biological variation, including a modest diurnal (time-of-day) pattern. TSH within the reference range is a reassuring data point, but on its own it does not capture every dimension of a patient's clinical thyroid status. Persistent symptoms in the context of a "normal" TSH deserve appropriate clinical evaluation with a prescriber — they are a reasonable basis for further discussion, not something to dismiss, but they do not by themselves establish that thyroid hormone treatment is inadequate or that a dose change is needed.

Free T4

Thyroxine (T4) circulates mostly bound to proteins (thyroxine-binding globulin, transthyretin, and albumin), with only a small free fraction considered biologically available. Free T4 testing estimates this unbound fraction and is used alongside TSH, particularly when pituitary function is in question, when TSH and symptoms don't align, or when monitoring certain treatments. T4 is often described as a relatively long-acting "prohormone" that is converted to the more biologically active T3 in peripheral tissues.

Free T3 and T4-to-T3 conversion

Triiodothyronine (T3) is the more biologically active thyroid hormone at the receptor level. Most circulating T3 is produced not by the thyroid gland directly but by peripheral conversion of T4 to T3 via deiodinase enzymes: of the roughly 33 µg of T3 produced daily, approximately 80% arises from peripheral conversion of T4, with only about 20% from direct thyroidal secretion.^[1] The American Thyroid Association's treatment guidelines associate patient dissatisfaction with levothyroxine therapy with genetic variation in deiodinase enzymes, but do not establish "impaired T4-to-T3 conversion" as a distinct, validated clinical diagnosis warranting routine additional treatment.^[1] Free T3 testing is used less routinely than TSH and free T4 in standard screening — the American Thyroid Association describes free T3 measurement as "often not reliable and therefore not typically helpful"^[2] and notes that testing for T3 "doesn't help much in diagnosing hypothyroidism"^[3] — though it can still be clinically relevant in more targeted situations, such as evaluating patients on T3-containing therapy.

Thyroid peroxidase antibodies

Thyroid peroxidase antibodies (TPOAb) are relevant when autoimmune thyroid disease is suspected; positive TPOAb (and/or anti-thyroglobulin antibodies) in a patient with hypothyroidism support a diagnosis of Hashimoto's thyroiditis and can have prognostic relevance in some situations, such as pregnancy or a borderline TSH.^[2] The American Thyroid Association notes that while antibody testing is helpful for initial diagnosis, following antibody levels over time is not useful for detecting the development of hypothyroidism or for monitoring response to therapy^[2] — antibody testing is not part of every routine thyroid panel and is ordered based on clinical context.

Reference ranges vs. clinical context

Thyroid reference ranges are statistical constructs derived from a reference population, and where an individual patient's result falls relative to that range needs to be interpreted alongside age, pregnancy status, symptoms, and the reason testing was ordered. A result at the edge of a reference range is not automatically "normal" or "abnormal" in a clinically meaningful sense — that judgment depends on context that a prescriber, not the number in isolation, is positioned to weigh.

Medication timing and factors affecting interpretation

Several factors can affect thyroid test interpretation: the timing of a blood draw relative to a levothyroxine or other thyroid-medication dose (levothyroxine is commonly taken in a fasting state, separated from certain other medications and supplements that can affect absorption); biotin supplementation, which can interfere with some thyroid immunoassays; acute illness (which can transiently alter thyroid values, sometimes called "sick euthyroid" patterns); and pregnancy, which shifts reference ranges. Consistent timing of testing relative to medication dosing makes results more comparable over time.

Levothyroxine, liothyronine, combination and desiccated therapy

Levothyroxine (synthetic T4) is the standard first-line treatment for hypothyroidism in most patients, relying on the body's own peripheral conversion of T4 to T3. Liothyronine (synthetic T3) is sometimes added or used alone in specific circumstances, generally when a patient does not achieve adequate symptom control on T4 monotherapy despite normal labs, though this is an individualized decision rather than a routine next step. Combination T4/T3 therapy and desiccated thyroid extract (derived from animal thyroid gland, containing both T4 and T3 in a fixed, biologically-determined ratio rather than a precisely titratable one) are used by some prescribers for some patients. The American Thyroid Association's clinical practice guidelines found "no consistently strong evidence for the superiority of alternative preparations (e.g., levothyroxine–liothyronine combination therapy, or thyroid extract therapy, or others) over monotherapy with levothyroxine, in improving health outcomes," and recommend that levothyroxine monotherapy remain the standard of care for hypothyroidism.^[1] That conclusion is about the general hypothyroid population, not an absolute rule for every patient — it means the evidence does not support combination or desiccated therapy as a routine, universal substitute for levothyroxine monotherapy, not that it is never an appropriate, individualized choice for a specific patient in consultation with their prescriber.

Compounded thyroid preparations

Compounded thyroid preparations allow a prescriber to specify a customized T4/T3 ratio or dose strength not available in a commercial fixed-ratio product, which can be useful for patients who need a dose or ratio between standard commercial increments, or who have a documented intolerance to an excipient in an FDA-approved product. The American Thyroid Association's clinical practice guidelines recommend against the routine use of compounded thyroid hormone preparations, citing low-quality evidence to support their use in place of FDA-approved products — a weak recommendation, not an absolute prohibition, that leaves room for individualized, prescriber-directed use in specific circumstances.^[1] As with any compounded thyroid product, dosing precision and consistency between preparations are important considerations that a prescriber weighs alongside the potential benefit of individualized dosing, and compounded preparations do not undergo the same FDA premarket review as FDA-approved commercial products.